Under the terms of the agreement, Eisai has the option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules that emerge from their research collaboration with Numab. In exchange, Numab will receive from Eisai an upfront payment and research funding and is eligible to receive success fees, milestone...